Drug Trial Radar · NCT00712933
A Continuation Trial for Subjects With Lupus That Completed Protocol HGS1006-C1056 or HGS1006-C1057
Last checked: Nov 20, 2026Latest source record: Dec 5, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
738
Actual
Start
May 30, 2008
Primary completion
Dec 9, 2016
Study completion Dec 9, 2016
Sponsor
- Lead sponsor
- Human Genome Sciences Inc., a GSK CompanyIndustry
- Sponsor type
- Industry
- Collaborators
- GlaxoSmithKline
- First posted
- Jul 10, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a long-term continuation study to provide continuing treatment to subjects with SLE.
Conditions
- Systemic Lupus Erythematosus
Interventions
belimumabDrug
Recombinant, fully human, monoclonal antibody Comparison of the 1 mg/kg and 10 mg/kg dose of belimumab given IV every 28 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events (AE)Time frame: Up to 9 years
- AE Rates by System Organ Class (SOC) During the StudyTime frame: Up to 9 years
- Number of Participants With Serious Adverse Events (SAE)Time frame: Up to 9 years
- SAE Rates by SOC During the StudyTime frame: Up to 9 years
- Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time PointsTime frame: Baseline and up to 9 years
- Change From Baseline in Platelets (Plt), Lymphocytes (Lymp), Leukocytes (Leu), Eosinophils (Eos), Basophils (Baso), Monocytes (Mono), Neutrophils (Neu), Neutrophils Band Form (NeuBF), Neutrophils Segmented (NeuS) at the Indicated Time PointsTime frame: Baseline and up to 9 years
- Change From Baseline in Hemoglobin (Hg) at the Indicated Time PointsTime frame: Baseline and up to 9 years
- Change From Baseline in Hematocrit at the Indicated Time PointsTime frame: Baseline and up to 9 years
- Change From Baseline in Erythrocytes (Eryth) at the Indicated Time PointsTime frame: Baseline and up to 9 years
- Change From Baseline in Calcium (Ca), Carbon Dioxide (CO2), Chloride, Magnesium (Mg), Phosphate (Phos), Potassium (K), Sodium (Na) at the Indicated Time PointsTime frame: Baseline and up to 9 years
- Change From Baseline in Blood Urea Nitrogen/Creatinine (BUN/Cr) at the Indicated Time PointsTime frame: Baseline and up to 9 years
- Change From Baseline in Albumin (Alb) and Protein (Pro) at the Indicated Time PointsTime frame: Baseline and up to 9 years
- Change From Baseline in BUN and Glucose at the Indicated Time PointsTime frame: Baseline and up to 9 years
- Change From Baseline in Creatinine (Cr) and Urate at the Indicated Time PointsTime frame: Baseline and up to 9 years
- Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT) and Lactate Dehydrogenase (LDH) LevelsTime frame: Baseline and up to 9 years
- Change From Baseline in Bilirubin (Bili) LevelsTime frame: Baseline and up to 9 years
- Change From Baseline in Immunoglobulin G (IgG) LevelsTime frame: Baseline and up to 9 years
- Number of Participants With Immunogenic Response by YearTime frame: Up to 9 years
- Number of Participants With IgG Values Below the Lower Limit of Normal by YearTime frame: Up to 9 years
- Number of Participants With Shifts From Baseline in Prednisone and Other Steroids Dose by VisitTime frame: Up to 9 years
- Number of Participants With Any SLICC/ ACR Damage Index Worsening (Change > 0) From Baseline by VisitTime frame: Up to 9 years
Locations
110 sites in 28 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
Ciudad Autonoma Buenos Aires, Argentina
GSK Investigational Site
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
GSK Investigational Site
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
GSK Investigational Site
La Plata, Buenos Aires, Argentina
GSK Investigational Site
Rosario, Santa Fe Province, Argentina
GSK Investigational Site
San Miguel de Tucumán, Tucumán Province, Argentina
GSK Investigational Site
Vienna, Austria
GSK Investigational Site
Liège, Belgium
GSK Investigational Site
Campinas, Brazil
GSK Investigational Site
Rio de Janeiro, Brazil
GSK Investigational Site
São Paulo, Brazil
GSK Investigational Site
São Paulo, Brazil
GSK Investigational Site
Salvador, Estado de Bahia, Brazil
GSK Investigational Site
Goiânia, Goiás, Brazil
GSK Investigational Site
Juiz de Fora, Minas Gerais, Brazil
GSK Investigational Site
Recife, Pernambuco, Brazil
GSK Investigational Site
Porto Alegre, Rio Grande do Sul, Brazil
GSK Investigational Site
São Paulo, São Paulo, Brazil
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Montreal, Quebec, Canada
GSK Investigational Site
Santiago, Chile
GSK Investigational Site
Viña del Mar, Valparaiso, Chile
GSK Investigational Site
Barranquilla, Colombia
GSK Investigational Site
Bogotá, Colombia
GSK Investigational Site
Bucaramanga, Colombia
GSK Investigational Site
Medellín, Colombia
GSK Investigational Site
Brno-Bohunice, Czechia
GSK Investigational Site
Hradec Králové, Czechia
GSK Investigational Site
Olomouc, Czechia
GSK Investigational Site
Prague, Czechia
GSK Investigational Site
Suresnes, France
GSK Investigational Site
Berlin, Germany
GSK Investigational Site
Berlin, Germany
GSK Investigational Site
Kiel, Germany
GSK Investigational Site
Freiburg im Breisgau, Baden-Wurttemberg, Germany
GSK Investigational Site
Erlangen, Bavaria, Germany
GSK Investigational Site
Frankfurt am Main, Hesse, Germany
GSK Investigational Site
Hanover, Lower Saxony, Germany
Showing 40 of 110 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.